[Skip to Content]
[Skip to Content Landing]
July 26, 2000

How Often Should Patients With Diabetes Be Screened for Retinopathy?

Author Affiliations

Stephen J.LurieMD, PhD, Contributing EditorIndividualAuthor

JAMA. 2000;284(4):437-439. doi:10.1001/jama.284.4.436

To the Editor: We would like to commend Dr Vijan and colleagues1 for their contribution to cost-utility analysis of screening for patients with type 2 diabetes mellitus. We believe that studies of this nature are crucial for policymakers who will decide the direction of health care.

Critical to any cost-effective analysis, however, are the utility values used in the decision analysis process. As Vijan et al state, "The variable that had the largest impact on the effectiveness of screening was the utility placed on a year of blindness." In the study, they assigned a utility value of 0.69 to blindness.